Flucamed

Active Ingredient & Mechanism of Action

• Active Ingredient: Fluconazole.
• Mechanism: Flucamed selectively inhibits the fungal cytochrome P450 enzyme 14$\alpha$-demethylase. This blocks the conversion of lanosterol to ergosterol—an essential component of fungal cell membranes. The resulting membrane disruption impairs fungal cell permeability, growth, and replication (fungistatic effect).

Available Dosage Forms & Strengths

• Oral Capsules: Commonly available in 50 mg, 150 mg, and 200 mg strengths.
• Powder for Oral Suspension: Available as a reconstituted liquid formulation (e.g., 50 mg / 5 mL) for pediatric patients or individuals with difficulty swallowing capsules.

Clinical Indications

• Vaginal Candidiasis (Yeast Infection): Acute treatment (typically a single 150 mg dose) or long-term suppressive management.
• Oropharyngeal & Esophageal Candidiasis: Treatment of fungal thrush affecting the mouth, throat, or esophagus.
• Systemic & Mucosal Candidiasis: Management of invasive Candida infections, including urinary tract infections, peritonitis, or candidemia.
• Cryptococcal Meningitis: Treatment of active cryptococcal brain infections and long-term maintenance therapy to prevent relapse in immunocompromised patients (such as those with HIV/AIDS).
• Prophylaxis: Prevention of Candida infections in high-risk immunocompromised individuals, such as bone marrow transplant recipients or patients undergoing chemotherapy.

Key Pharmacokinetics

• Absorption: Exceptionally well absorbed following oral administration with a systemic bioavailability exceeding 90%. Absorption is not significantly affected by food intake.
• Distribution: Low plasma protein binding ($\sim 11\text{–}12\%$) allows extensive distribution into body tissues and fluids, including saliva, sputum, skin, and cerebrospinal fluid (CSF).
• Elimination & Half-Life: Long elimination half-life ($\sim 30\text{ hours}$), enabling convenient once-daily or single-dose regimens. Excreted primarily unchanged by the kidneys into the urine.

Administration Guidelines

• Usage: Administered orally with or without food.
• Dosing Regimen: Varies by condition—ranging from a single 150 mg dose for uncomplicated vaginal thrush to once-daily schedules for several weeks or months for systemic or meningeal infections.
• Renal Adjustments: Because it is cleared mainly through the kidneys, dosage reductions are required for patients with moderate to severe renal dysfunction.

Safety Profile & Considerations

• Common Side Effects: Headache, nausea, abdominal discomfort, diarrhea, dizziness, and mild skin rash.
• Precautions & Warnings:
  • Hepatic Monitoring: Potential for transient elevations in liver enzymes; caution and monitoring are advised during prolonged therapy.
  • Cardiac Risk (QT Prolongation): Can prolong the QT interval on an ECG, requiring caution in patients with underlying arrhythmias or electrolyte imbalances.
  • Pregnancy: High doses or chronic use during early pregnancy carry risks of fetal toxicity; single doses for vaginal candidiasis should only be taken if clearly advised by a doctor.
• Key Drug Interactions (CYP2C9 / CYP3A4 Inhibitor):
  • Oral Antidiabetics (Sulfonylureas): Prolongs half-life, increasing the risk of hypoglycemia.
  • Warfarin / Blood Thinners: Enhances anticoagulant effect, elevating bleeding risks.
  • Phenytoin & Carbamazepine: Increases plasma levels and potential toxicity of anticonvulsants.
  • Statins & Immunosuppressants: Can increase drug exposure and toxicity of co-administered agents.

Note: Flucamed is a prescription-only antifungal medication. Dosing schedules, treatment duration, and potential drug interactions should be evaluated under the supervision of a licensed healthcare professional.